Prelude began Phase 1 enrollment for PRT13722 after September 2026 FDA clearance and entered an October 2026 clinical trial collaboration with Eli Lilly and Company to evaluate abemaciclib and imlunestrant combinations in HR+/HER2- breast cancer.
PRLD · Prelude Therapeutics Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 60%
- Last earnings
- Nov 16, 2026
- Latest filing
- 10-Q · Nov 16
- Price history
- Sep 2020 to Nov 2026
Up next
Latest documents
Prelude Therapeutics began Phase 1 enrollment for PRT13722 in HR+/HER2- breast cancer, expects proof-of-concept data in the 2nd half of 2027, and expects cash to fund operations into the second quarter of 2028.
The first half is expected to bring clarity on whether Insight exercises its option, worth $100 million in non-dilutive financing. Initial proof-of-concept data for the CAT6 degrader program is anticipated in the second half of 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| complete and durable responses | 100% | November 2026 | — |
| Complete Response Rate as Monotherapy | 100% | November 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRLD
this stock
Prelude Therapeutics Inc
|
$258.63M | +11.4% | +73.4% | — | 5.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 23
Prelude began Phase 1 enrollment for PRT13722 after September 2026 FDA clearance and entered an October 2026 clinical trial collaboration with Eli Lilly and Company to evaluate abemaciclib and imlunestrant combinations in HR+/HER2- breast cancer.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRLD | -6.4% | -11.0% | -7.7% | -16.8% | +11.4% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +2.2% | -1.8% | +1.5% | -8.0% | +10.2% |